CAMP4's RNA Actuating Platform (RAP) maps regRNAs associated with every protein-coding gene in any cell type, and its programmable antisense oligonucleotide (ASO) therapeutics target the controlling regRNAs to upregulate gene expression to treat disease. This approach is applicable to a range of genetic diseases in which tunable increases in gene output can lead to meaningful therapeutic outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/21/22 | $100,000,000 | Series B |
5AM Ventures Andreessen Horowitz Enavate Sciences Gaingels Kraft Group Northpond Ventures Polaris Partners | undisclosed |
